The phase 2 AZALEA-TIMI 71 trial in AF shows "an overwhelming reduction" in major and clinically relevant nonmajor bleeding with investigational Factor XI inhibitor abelacimab vs rivaroxaban.
Frail patients with atrial fibrillation who were switched to a newer NOAC agent had more bleeding than those left on older vitamin K antagonists, without any benefit in terms of thromboembolic events.
Twelve months of edoxaban is superior to three months for the reduction of thrombotic events in patients with cancer and distal deep vein thrombosis (DVT), according to late breaking research.